ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 (GLP)

This study is not yet open for participant recruitment.
Verified by Assaf-Harofeh Medical Center, April 2007

Sponsored by: Assaf-Harofeh Medical Center
Information provided by: Assaf-Harofeh Medical Center
ClinicalTrials.gov Identifier: NCT00473733
  Purpose

Glucagon like peptides receptors expression in the stomach of diabetes type 2 Glucagon like peptides (GLP-1, GLP-2), are hormones secreted by L cells located along the gastrointestinal tract. These hormones are secreted after meals and have some roles in regulating the digestion process, absorption, and sending signals to the brain that regulate food consumption. GLP peptides affect peripheral targets and have an important homeostatic role. GLP-1 decreases the circulatory glucose level and GLP-2 has trophic effects which enable adequate intestine growth.

We aimed in our study to investigate the GLP-1 and GLP-2 receptor expression in different zones of the stomach in diabetes type 2 patients. If there are differences, it might explain the pathological gastric emptying in these patients.

Understanding the function of these peptides may lead to new therapeutic options for diabetic patients with delayed gastric emptying.

Methods: 20 diabetes type 2 patients with symptoms that need upper endoscopy will be included in the study and 20 controls aged 18-70 years. Patients with neurological disease will be excluded. During esophagogastroduodenoscopy 3 biopsies will be taken from the antrum, corpus and cardia. The biopsies will be stored in -70. After RNA extraction the GLP receptors expression will established by real time PCR method. Patients with different expression compared to control will undergo isotopic scan for gastric emptying.


Condition Intervention Phase
Diabetes Mellitus Type 2
Procedure: GLP receptors expression
Procedure: ESOPHAGOGASTRODUODENOSCOPY
Phase IV

MedlinePlus related topics:   Diabetes    Endoscopy   

ChemIDplus related topics:   Glucagon   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Diagnostic, Non-Randomized, Open Label, Active Control, Crossover Assignment
  Eligibility
Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • 20 diabetes type 2 patients with symptoms that need upper endoscopy will be included in the study and 20 controls aged 18-70 years

Exclusion Criteria:

  • Patients with neurological disease will be excluded
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00473733

Contacts
Contact: Efrat Broide, MD     972-8-9779722     efibroide@yahoo.com    

Locations
Israel
Assaf Harofeh Medical Center     Not yet recruiting
      Zerifin, Israel, 70300
      Contact: eFRAT Broide, MD     972-8-9779722     efibroide@yahoo.com    
      Principal Investigator: Efrat Broide, MD            

Sponsors and Collaborators
Assaf-Harofeh Medical Center

Investigators
Principal Investigator:     Efrat Broide, MD     Ethic committee of Asaaf Harofeh Medical Center    
  More Information

Study ID Numbers:   65/07
First Received:   May 13, 2007
Last Updated:   May 14, 2007
ClinicalTrials.gov Identifier:   NCT00473733
Health Authority:   Israel: "Ethic committee of Assaf Harofeh Medical Center"

Keywords provided by Assaf-Harofeh Medical Center:
PATIENTS WITH DIABETES MELLITUS TYPE 2  
UNDERGO UPPER ENDOSCOPY  
BIOPSIES FOR GLP RECEPTORS EXPRESSION  
PCR ANALYSIS  

Study placed in the following topic categories:
Metabolic Diseases
Glucagon
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Endocrinopathy
Metabolic disorder
Glucose Metabolism Disorders

ClinicalTrials.gov processed this record on September 05, 2008




Links to all studies - primarily for crawlers